Vascular Occlusion Evolution in Endovascular Reperfusion Candidates Transferred from Primary to Comprehensive Stroke Centers.


Journal

Cerebrovascular diseases (Basel, Switzerland)
ISSN: 1421-9786
Titre abrégé: Cerebrovasc Dis
Pays: Switzerland
ID NLM: 9100851

Informations de publication

Date de publication:
2020
Historique:
received: 27 06 2020
accepted: 23 08 2020
pubmed: 23 10 2020
medline: 1 12 2020
entrez: 22 10 2020
Statut: ppublish

Résumé

The evolution of the symptomatic intracranial occlusion during transfers from primary stroke centers (PSCs) to comprehensive stroke centers (CSCs) for endovascular treatment (EVT) is not widely known. Our aim was to identify factors related to partial or complete recanalization (REC) at CSC arrival in patients with a documented large vessel occlusion (LVO) in PSC transferred for EVT evaluation to better define the workflow at CSC of this group of patients. We conducted an observational, multicenter study from a prospective, government-mandated, population-based registry of stroke patients with documented LVO at PSC transferred to CSC for EVT from January 2017 to June 2019. The primary end point was defined as partial or complete REC that precluded EVT at CSC arrival (REC). We evaluated the association between baseline, treatment variables and time intervals with the presence of REC. From 589 patients, the rate of REC at CSC was 10.5% in all LVO patients transferred from PSC to CSC for EVT evaluation. On univariate analysis, lower PSC-NIHSS (median 12vs.16, p = 0.001), tPA treatment at PSC (13.7 vs. 5.0%; p = 0.001), presence of M2 occlusion on PSC (16.8 vs. 9%; p = 0.023), and clinical improvement at CSC arrival (21.7 vs. 9.6% p = 0.001) were associated with REC at CSC. On multivariate analysis, clinical improvement at CSC arrival (p < 0.001, OR: 5.96 95% CI: 2.5-13.9) and PSC tPA treatment predicted REC (p = 0.003, OR: 4.65, 95% CI: 1.73-12.4). REC at CSC arrival occurs exceptionally in patients with a documented LVO on PSC. Repeating a second vascular study before EVT would not be necessary in most patients. Despite its modest effect, tPA treatment at PSC was an independent predictor of REC.

Sections du résumé

BACKGROUND
The evolution of the symptomatic intracranial occlusion during transfers from primary stroke centers (PSCs) to comprehensive stroke centers (CSCs) for endovascular treatment (EVT) is not widely known. Our aim was to identify factors related to partial or complete recanalization (REC) at CSC arrival in patients with a documented large vessel occlusion (LVO) in PSC transferred for EVT evaluation to better define the workflow at CSC of this group of patients.
METHODS
We conducted an observational, multicenter study from a prospective, government-mandated, population-based registry of stroke patients with documented LVO at PSC transferred to CSC for EVT from January 2017 to June 2019. The primary end point was defined as partial or complete REC that precluded EVT at CSC arrival (REC). We evaluated the association between baseline, treatment variables and time intervals with the presence of REC.
RESULTS
From 589 patients, the rate of REC at CSC was 10.5% in all LVO patients transferred from PSC to CSC for EVT evaluation. On univariate analysis, lower PSC-NIHSS (median 12vs.16, p = 0.001), tPA treatment at PSC (13.7 vs. 5.0%; p = 0.001), presence of M2 occlusion on PSC (16.8 vs. 9%; p = 0.023), and clinical improvement at CSC arrival (21.7 vs. 9.6% p = 0.001) were associated with REC at CSC. On multivariate analysis, clinical improvement at CSC arrival (p < 0.001, OR: 5.96 95% CI: 2.5-13.9) and PSC tPA treatment predicted REC (p = 0.003, OR: 4.65, 95% CI: 1.73-12.4).
CONCLUSION
REC at CSC arrival occurs exceptionally in patients with a documented LVO on PSC. Repeating a second vascular study before EVT would not be necessary in most patients. Despite its modest effect, tPA treatment at PSC was an independent predictor of REC.

Identifiants

pubmed: 33091908
pii: 000511063
doi: 10.1159/000511063
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

550-555

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Alan Flores (A)

Stroke Unit, Neurology Department, Hospital Universitari Joan XXIII, Tarragona, Spain, alanflo2507@hotmail.com.

Xavier Ustrell (X)

Stroke Unit, Neurology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

Laia Seró (L)

Stroke Unit, Neurology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

Anna Pellisé (A)

Stroke Unit, Neurology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

Paula Rodriguez (P)

Stroke Unit, Neurology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

Jaume Viñas (J)

Stroke Unit, Neurology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

Marc Ribó (M)

Stroke Unit, Neurology Department, Hospital Universitari Vall D' Hebron, Barcelona, Spain.

Jurek Krupinski (J)

Neurology Department, Hospital Althaia, Manresa, Spain.

Natalia Más (N)

Neurology Department, Hospital Mutua Terrasa, Barcelona, Spain.

Sonia Garcia (S)

Neurology Department, Hospital Moises Broggi, Barcelona, Spain.

Ernesto Palomeras Soler (E)

Neurology Department, Hospital de Mataró, Mataró, Spain.

Dolores Cocho (D)

Neurology Department, Hospital de Granollers, Granollers, Spain.

David Canovas (D)

Neurology Department, Hospital Parc Tauli, Sabadell, Spain.

Francisco Purroy (F)

Stroke Unit, Neurology Department, Hospital Arnau de Vilanova, Lleida, Spain.

Joaquim Serena (J)

Stroke Unit, Neurology Department, Hospital Univri Josep Trueta, Girona, Spain.

Jose Zaragoza-Brunet (J)

Stroke Unit, Neurology Department, Hospital Verge de la Cinta, Tortosa, Spain.

Victor Obach (V)

Stroke Unit, Neurology Department, Hospital Clinic, Barcelona, Spain.

Natalia Perez de la Ossa (N)

Stroke Unit, Neurology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Stroke Programme, Agency for Health Quality and Assessment of Catalonia, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Pere Cardona (P)

Stroke Unit, Neurology Department, Hospital Universitari Bellvitge, Barcelona, Spain.

Carlos A Molina (CA)

Stroke Unit, Neurology Department, Hospital Universitari Vall D' Hebron, Barcelona, Spain.

Sonia Abilleira (S)

Stroke Programme, Agency for Health Quality and Assessment of Catalonia, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Marta Rubiera (M)

Stroke Unit, Neurology Department, Hospital Universitari Vall D' Hebron, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH